IP Library Granted Patent US 9,321,849
Granted Patent B2
US 9,321,849 · App. 12/979,787 · Granted Apr 26, 2016

Uranium-chelating peptides and uses thereof

Inventors: Claudio Vita (Gif sur Yvette, FR); Loïc Le Clainche (Paris, FR); Véronique Monjardet (Paris, FR)
Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
C07K19/00C07K14/4728A61K38/00C07K2319/00G01N2333/4727
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,321,849
App. No.
12/979,787
Granted
Apr 26, 2016
Kind
B2
Abstract

The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.

Claims (16)

1. A peptide comprising one of the sequences SEQ ID Nos. 4-7 or SEQ ID Nos. 9-12.

2. The peptide as claimed in claim 1 , wherein cysteines at positions 13 and 29 of said sequences are connected via a disulfide bridge.

3. The peptide as claimed in claim 1 , wherein it is conjugated to at least one fluorophore.

4. The peptide as claimed in claim 3 , wherein it is conjugated to two different fluorophores.

5. The peptide as claimed in claim 3 wherein said fluorophore is a fluorescent protein selected from: EBFP, ECFP, EYFP, EGFP, DsRed, CopGFP and PhiYFP.

6. The peptide as claimed in claim 3 wherein said fluorophore is selected from dansyl, coumarin, fluorescein and Alexa derivatives.

7. The peptide as claimed in claim 1 , wherein it is associated with at least one molecule that allows targeting to the kidney and/or to the bone.

8. The peptide as claimed in claim 1 , wherein it is associated with a molecule that promotes its excretion in vivo.

9. A polypeptide comprising the concatenation of at least two identical or at least two different peptides as claimed in claim 1 .

10. A peptide composition comprising at least one polypeptide as claimed in claim 9 and at least one suitable vehicle.

11. A fusion protein consisting of the in-frame fusion of the sequence of at least one peptide as claimed in claim 1 , with the sequence of protein selected from the group consisting of calmodulin, chameleon proteins, and proteins having a helix-loop-helix type motif, capable of binding calcium.

12. The fusion protein as claimed in claim 11 wherein it is conjugated to at least one fluorophore as defined in claim 5 .

13. The fusion protein as claimed in claim 12 , wherein one of the ends of said protein is coupled to a fluorescence donor, and the other is coupled to a fluorescence acceptor.

14. The fusion protein as claimed in claim 13 , wherein it comprises, at one of its ends, the sequence of EBFP or ECFP and, at the other end, the sequence of EGFP or of EYFP.

15. A kit for detecting a contamination with uranium comprising at least one of: a peptide as claimed in claim 1 , a polypeptide derived from said peptide, a peptide composition comprising said peptide, a fusion protein derived from said peptide, an antibody that binds selectively to said peptide, or modified prokaryotic or eukaryotic cells modified with a regulatory system that includes said peptide as a regulator or repressor of a gene encoding a bioluminescent protein.

16. The fusion protein as claimed in claim 11 wherein it is conjugated to at least one fluorophore selected from the group consisting of dansyl, coumarin, fluorescein and Alexa derivatives.

Assignments (2)
CHANGE OF NAME Recorded Jul 19, 2016
From: COMMISSARIAT A L'ENERGIE ATOMIQUE
To: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Reel/Frame 039389/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2016
From: SAUVAGE-VITA, MIREILLE; VITA, FABIO; VITA, ELENA; LE CLAINCHE, LOÏC; MONJARDET, VÉRONIQUE
To: COMMISSARIAT A L'ENERGIE ATOMIQUE
Reel/Frame 037800/0031 →
Priority Claims (1)
FR 03 08211 · Jul 4, 2003 · national
Continuity (2)
Division 10562323
Related Publication 20110093964A1 · Apr 21, 2011